Mucopolysaccharidosis (MPS) IIIB is an inherited lysosomal storage disease, caused by the deficiency of a-N-acetylglucosaminidase (NaGlu), resulting in severe global neurological involvement with high mortality. One major hurdle in therapeutic development for MPS IIIB is the presence of the blood-brain barrier, which impedes the global central nervous system (CNS) delivery of therapeutic materials. In this study, we used a minimal invasive strategy, combining an intravenous (i.v.) and an intracisternal (i.c.) injection, following an i.v. infusion of mannitol, to complement the CNS delivery of adeno-associated viral (AAV) vector for treating MPS IIIB in young adult mice. This treatment resulted in a significantly prolonged lifespan of MPS IIIB mice (11.1-19.5 months), compared with that without treatment (7.9-11.3), and correlated with significantly improved behavioral performances, the restoration of functional NaGlu, and variable correction of lysosomal storage pathology in the CNS, as well as in different somatic tissues. This study demonstrated the great potential of combining i.v. and i.c. administration for improving rAAV CNS gene delivery and developing rAAV gene therapy for treating MPS IIIB in patients.
Introduction
Mucopolysaccharidosis (MPS) IIIB is an autosomalrecessive disorder caused by a single gene deficiency coding a lysosomal enzyme, a-N-acetylglucosaminidase (NaGlu). 1 The lack of NaGlu leads to the intralysosomal accumulation of an undegraded glycosaminoglycan (GAG), heparan sulfate, in cells of the central nervous system (CNS) and a broad range of somatic tissues/ organs. 2 Recent studies have demonstrated more complex pathological consequences secondary to heparan sulfate storage in neurons of MPS IIIB mouse brain. 3 The major problem in MPS III patients, including subtypes A, B, C and D, as well as many other lysosomal storage diseases (LSDs), is the subsequent global degenerative CNS pathology involving both neuronal and nonneuronal cells, causing severe progressive neurological deficits, ultimately leading to premature death. No treatment is currently available for MPS IIIB. The therapies currently available for other MPS disorders, such as bone marrow transplantation 4, 5 and recombinant enzyme replacement therapy (ERT), 6, 7 are not recommended for MPS III. This is due to the fact that the CNS pathologies in MPS III are global, and neither the peripherally delivered bone marrow stem cells nor the recombinant enzymes can be efficiently delivered to the CNS through the blood-brain barrier (BBB).
Like other LSDs, MPS IIIB is considered an ideal candidate for gene therapy, since it is a single-gene disorder in which tight regulation of the gene product may not be required. 8 Moreover, NaGlu shares many properties with other lysosomal enzymes, which can be secreted and taken up by neighboring cells and transported to the lysosomes, resulting in broader distribution via a bystander effect. [9] [10] [11] Generally speaking, for MPS disorders, only 1-2% residual enzyme activity may be needed to normalize cell function. Therefore, it would not be necessary to transduce all cells for effective MPS IIIB treatment.
One gene therapy approach is the use of recombinant adeno-associated virus (rAAV) vector to carry a replacement for the defective NaGlu gene. AAV belongs to a diverse group of helper-dependent parvoviruses with no known associated pathology in man, although it may remain latent in many human tissues. 12 The wellestablished rAAV vector system has been shown to mediate long-term gene expression and functional correction in both the CNS and in multiple somatic tissues of different animal models. 13, 14 Previous studies have also demonstrated rAAV-mediated long-term transgene expression in both neuronal and non-neuronal cells, resulting in the correction of lysosomal storage in MPS I, MPS IIIB and MPS VII animals after direct injection into the mouse brain. [15] [16] [17] [18] [19] The most challenging aspect of MPS IIIB therapeutic studies is to develop treatment for the degeneration of CNS function, for which the major obstacle is the BBB, which segregates the CNS from the blood circulation system and impedes effective delivery of therapeutic reagents. 20 Another critical issue is how to achieve a global distribution of transgene expression, since the CNS pathology of MPS IIIB is found in all parts of the brain. Previous gene delivery studies have shown efficient expression of recombinant enzymes and the correction/prevention of CNS lysosomal GAG accumulation following direct injection of rAAV vectors into the brain, although the correction was limited to the brain areas immediately surrounding or related to the infusion sites, 17, 19, 21 despite the observed retrograde AAV vector infection and axonal transport of recombinant lysosomal enzymes in animals. 22, 23 However, a recent study demonstrated widespread transgene expression in the CNS accompanied by improved behavior and neuropathology in MPS IIIB mice by direct brain injection, 24 though this strategy may be problematic in the context of a large animal or in humans. Intravenous (i.v.) injection of rAAV or retroviral vectors in MPS animal models during the neonatal period resulted in long-term expression of recombinant b-glucuronidase and the correction of lysosomal accumulation in both somatic tissue and the CNS, which persisted into adulthood. [25] [26] [27] [28] However, the BBB may still be permeable in neonatal mice, while, in humans, the BBB is completely formed at birth. Furthermore, most patients with MPS or other LSD are not diagnosed until several years of age. Therefore, adult mice provide a better model for BBB challenges in therapeutic strategies for MPS in humans.
Numerous strategies have been developed to overcome the difficulties of CNS drug delivery posed by the BBB, including drug manipulation, the use of escort systems, transient osmotic BBB disruption and direct CNS delivery bypassing the BBB. 29 However, the BBB remains an obstacle to treating global CNS disorders, since the vascular route is considered the most direct approach to therapeutic delivery to all parts of brain. Previous studies have demonstrated the access of substances to the CNS in humans and experimental animals after intra-arterial administration of mannitol. 29 Many human clinical studies have been performed with intra-arterial (carotid) infusion of mannitol, or other sugar solutions, to open the BBB and enable CNS delivery of chemotherapeutic reagents. 30, 31 Improved survival in patients with brain tumors has been demonstrated 30, 31 and the intra-arterial infusion of mannitol did not cause obvious BBB damage. 32 Mannitol has also been tested in preclinical studies to achieve the entry of a wide range of macromolecular substances into brain, including enzymes, antibodies and viral vectors. 29 I.v. infusion of mannitol has been a routine clinical practice in treating various human diseases.
Previous work in our laboratory demonstrated that, in adult mice, pretreatment with an i.v. infusion of mannitol facilitated the CNS entry of i.v.-delivered rAAV2 reporter vector, and a diffuse global distribution of transduced neuronal and non-neuronal cells throughout the CNS. 13 No CNS delivery was observed without mannitol pretreatment. In addition, mannitol pretreatment also enhanced the delivery of rAAV injected into the posterior cistern of adult mice, beyond the BBB, resulting in a deep periventricular, though not global, distribution of transduced cells in the CNS, likely through the effects of the re-establishment of fluid balance within the brain tissues. 13 These observations provide a foundation for the therapeutic use of mannitol-enhanced rAAV gene delivery for the correction of the CNS manifestations of MPS IIIB.
In this study we determined the therapeutic impact of these rAAV vector delivery strategies by combining an i.v. and an intracisternal (i.c.) injection to deliver a therapeutic AAV2-NaGlu vector into the CNS of 4-8-week-old MPS IIIB mice. The rationale for this treatment regimen is to provide high-level transduction in areas with cerebral spinal fluid contact with the i.c. delivery, such that secreted enzyme can be dispersed to distant CNS regions, and diffuse global transduction with the i.v. delivery, to reach deeper parenchymal tissues. We demonstrated a broad distribution of rNaGlu expression in the brain, as well as multiple somatic tissues/organs, and correction of lysosomal storage in both the CNS and somatic tissues. Most importantly, we demonstrated a significant prolonged lifespan and improvement in behavioral performance, suggesting the correction of neurological disorders as a result of the treatment in adult MPS IIIB mice.
Results
We used a combined i.v. and i.c. injection strategy to evaluate the therapeutic efficacy of rAAV gene delivery to treat the CNS disorders in a mouse model of MPS IIIB. A therapeutic rAAV2 vector, expressing human NaGlu (hNaGlu) driven by a cytomegalovirus (CMV) promoter, was delivered into 4-8-week-old MPS IIIB mice (n ¼ 37), following an i.v. infusion of mannitol. An additional set of MPS IIIB mice (n ¼ 38), including subjects given sham injections of mannitol and phosphate-buffered saline (PBS) (n ¼ 28), or untreated MPS IIIB mice (n ¼ 10), served as negative controls. The wild-type littermates (n ¼ 38) served as normal controls. Following the rAAV, or sham treatment, a subset of the animals was assessed for behavioral function. All animals were monitored until the late-stage clinical manifestations of MPS IIIB, such as urine retention, rectal prolapse, protruding penis and spinal curvature, became irreversible, or else, in the case of the wild-type control mice, until 24 months of age or older. Therefore, the end points of the experiments were determined based on the lifespan of the mice. Biochemical, histopathological and ultrastructural evaluations of brain and multiple somatic tissues were performed at the end of the observation period for each mouse, to assess the rAAV-mediated expression of functional recombinant NaGlu, and the correction of lysosomal storage in these tissues. In this study, the lifespan of the non-treated MPS IIIB mice varied from 7.9 to 11.3 months of age, while the wild-type mice lived up to 30 months. or greater) . The remaining five treated mice (26%) had lifespans that fell within the range of untreated MPS IIIB mice (less than 12 months). All subjects, treated and untreated, belonged to the same age-matched group of littermates from the breeding colony (within 3-4 weeks). Additional treated and control animals were not evaluated for behavioral performance, due to unavailability at the time of testing.
One of the previously observed behavioral deficits of MPS IIIB mice was reduced vertical activity and rearing movements in a novel open field. In our assay, MPS IIIB male mice, including both the non-treated group and the rAAV-treated animals with shorter lifespans (less than 1 year), also displayed significantly reduced vertical activity and rearing movements in a novel open field, compared to the wild-type controls (Po0.05; Figure 2 ). These differences emerged in the last half of the 1-hour session. In contrast, the i.v.+i.c.-treated MPS IIIB males with the extended lifespans (412 months) had normal levels of vertical movements, with similar rearing activity to the wild-type male mice throughout the activity test (Figure 2) . Thus, the improved behavioral performance correlated with longevity in the treated male mice, supporting the rAAV therapeutic effect in the CNS. Female MPS IIIB mice, treated or untreated, did not show significantly reduced activity compared with wildtype female mice in this assay.
In the visual cue task in the Morris water maze, the untreated MPS IIIB mice (both male and female) displayed significantly longer latencies to reach the visible platform, as well as deficient swimming ability, across all 3 days of testing (Po0.05; Figure 3 ). The same pattern was observed in those MPS IIIB mice that were treated with rAAVNaGlu, but did not respond with extended lifespans (5/19). In contrast, the i.v.+i.c.-treated MPS IIIB mice that ultimately had extended lifespans (14/19) displayed latencies to escape the water that were comparable to the wild-type mice by the 3rd day of testing, and normal swimming speeds for all three test days.
In three additional behavioral tests, the elevated plus maze, the rotarod and the prepulse inhibition of acoustic startle response, the performance of the untreated MPS IIIB mice was not significantly different from the normal mouse controls (data not shown).
Overall, the observable behavioral improvements in the neurological symptoms of the treated MPS IIIB mice correlated with extended life spans (412 months). The rAAV-treated animals with life spans near or within the range of the non-treated animals (o12 months) evidenced deficits that were characteristic of MPS IIIB neurodegeneration.
Broad distribution of rNaGlu and significant levels of NaGlu activity in the CNS
At the end of the observation periods, when physical deterioration symptoms had become irreversible, This distribution pattern of transgene expression was similar to that observed in our previous study using a self-complementary rAAV2-CMV-green fluorescent protein (GFP) vector i.c. injected into mice pretreated with mannitol. However, we did not observe the pattern of diffuse global CNS expression of NaGlu that we expected based on our previous GFP studies using an i.v. vector injection with mannitol pretreatment. No visible IHC staining signal was seen in the brains of the non-treated and wild-type control mice (the hNaGlu antibody does not crossreact with the mouse enzyme). We also directly measured NaGlu enzyme activity in MPS IIIB brain tissues to determine the efficiency and persistence of recombinant hNaGlu expression in the Increased lifespan and improved behavioral performances H Fu et al CNS after rAAV gene delivery. Transverse cryostatsectioned brain tissue samples (n ¼ 10 each) at the forebrain (FB), midbrain (MB) and hindbrain (HB) levels, were processed and assayed for NaGlu activity. The treatment with rAAV vector resulted in a significant level of NaGlu activity in all assayed brain samples ( Figure 5 ). Wild-type levels (4.370.2 units/mg) of NaGlu activity, or higher, were achieved in most tested brain tissues at MB (3.773.1) and HB (10.178.8) ( Figure 5 ). No detectable NaGlu activity was observed in the brains of shamtreated MPS IIIB mice (n ¼ 10). In wild-type mice (n ¼ 10), the NaGlu activity levels were similar across different brain areas, illustrating the ubiquitous distribution of the enzyme in the normal brain. This demonstrated that the rAAV-mediated restoration of functional rNaGlu in the CNS was long-term, and the improvements in survival and behavioral performance were not solely due to transient degradation of stored GAG in treated MPS IIIB mice.
The expression of rNaGlu in somatic tissues
To determine the effects of i.v.+i.c. rAAV delivery on somatic tissues/organs, multiple somatic tissues were assayed for the expression of rNaGlu. In the rAAVtreated MPS IIIB mice, NaGlu enzyme activity was detected in all tissues assayed, including liver (10-100% of wt level), kidney (1-3%), spleen (1-13%), heart (2-30%), lung (2-15%), intestine (1-5%) and skeletal muscle (10-30%) (Figure 6a ). No detectable NaGlu activity was observed in the somatic tissues of shamtreated and non-treated MPS IIIB control mice. The mouse liver tissues were also assayed by IHC to visualize the distribution of hNaGlu expression. In MPS IIIB mice treated with the rAAV vector, the hNaGlu was detected in 15-20% of liver cells (Figure 6b Increased lifespan and improved behavioral performances H Fu et al cells appeared to be hepatocytes. The hNaGlu was not detected in the livers of wild-type or non-treated MPS IIIB control mice. Although we had detected NaGlu enzyme activity in other somatic tissues in treated mice, no other positive-IHC staining was observed, again, suggesting a relatively low sensitivity with this antibody. These data are consistent with the propensity of the liver to take up the vast majority of i.v.-injected AAV2 vector, with or without mannitol pretreatment.
13
The CNS and somatic correction of lysosomal storage by rAAV gene delivery Several different methods, including direct quantitation of GAG, histopathology, and transmission electron microscopy (TEM) were used to evaluate the rAAVNaGlu-mediated correction of lysosomal storage in somatic and CNS tissues in MPS IIIB mice. The i.v. plus i.c. treatment with the rAAV vector led to a complete (100%) correction of GAG storage in liver (Po0.01) and reduction of GAG accumulation in spleen, heart, lung and skeletal muscle (Po0.05) (Figure 7a Because the baseline level of GAG in the CNS tissue of non-treated MPS IIIB mice was normally very low and variable, histopathology, rather than GAG content, was used to assess the correction of lysosomal storage in the brain. We observed a decrease in lysosomal storage, as evidenced by reductions in the size and number of vacuolated lysosomes, in broad brain areas of rAAVtreated MPS IIIB mice, compared to the non-treated MPS IIIB mice (Figure 8) , although a complete clearance of vacuoles was not seen.
Discussion
Improved survival is considered the most important and clinically significant result in evaluating the benefit of therapies. We successfully demonstrated the significant long-term therapeutic efficacy of rAAV gene therapy, by achieving a significantly prolonged lifespan and improved behavioral performances in MPS IIIB mice, using a non-surgical CNS vector delivery strategy developed in our laboratory. We also demonstrated a broad restoration of functional NaGlu enzyme in the CNS, leading to therapeutic correction in MPS IIIB mice. Most of the previous successful studies using i.v. viral gene delivery 
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for correction of LSDs in the CNS have been performed in neonate animals, 25, 27, 33, 34 before the complete formation of the blood-brain barrier. This modality is unlikely to be available in human patients, where the BBB is fully formed at birth. Previous studies using direct vector injection into the brain also showed CNS correction in MPS animal models, including MPS IIIB mice, though primarily limited to regions surrounding or related to the injection site. [16] [17] [18] [19] In a more recent study, Cressant et al. 24 achieved widespread distribution of the transgene product in MPS IIIB mice from a direct intrastriatal injection, and demonstrated therapeutic improvement.However, the CNS pathology of MPS IIIB is global, involving both neuronal and non-neuronal cells, and global therapeutic effects from a direct injection will become more challenging when scaled to the size of the human brain. We have previously shown that we could achieve broad CNS gene delivery with rAAV in young adult mice, using an i.v. infusion of mannitol to transiently open the BBB. 13 The mannitol pretreatment both enabled the CNS entry of i.v.-injected rAAV vector, and enhanced the spread of i.c.-delivered rAAV vector in CNS tissues. 13 Using the strategy of combining an i.v. and an i.c. injection, we have significantly delayed the progress of the CNS disease manifestation, and extended survival in MPS IIIB mice, though this treatment did not effect a complete cure. The high mortality and premature death are largely attributable to the neurological consequences of MPS IIIB in the mouse model and in human patients, 1 and the significantly increased survival is the most critical measure for therapeutic impacts. We therefore believe that the achievement in this study is a significant advance toward the treatment of MPS IIIB.
Our data demonstrated a somewhat variable response to the rAAV gene therapy in terms of survival, though most of the treated mice had significantly longer lifespans. The long-term increased survival correlated with improved behavioral performances measured at earlier time points. The reason for the variable therapeutic impact is not clear, though we have observed that the CNS transduction efficiency is critically dependent on the timing of vector infusion after mannitol administration (unpublished). Alternatively, the variation may be due to individual differences relating to the severity of the disease. While NaGlu deficiency is clearly the primary cause of MPS IIIB pathology, secondary effects on lysosomal degradation processes may also contribute to the disease. Additional analyses of the lysosomal Increased lifespan and improved behavioral performances H Fu et al storage pathology can provide powerful new metrics for the evaluation of therapeutic efficacy. 24 It is likely that the i.c./mannitol-delivered rAAV vector played the more substantial role in the therapeutic impact on the CNS disorder in this study, since a relatively large amount of vector could be safely infused into the posterior cistern, and the vectors had broad contact with the brain due to the large surface exposed to the CSF. This distribution pattern of transgene expression was similar to that observed in our previous study using a self-complementary rAAV2-CMV-GFP vector i.c. injected into mice pretreated with mannitol. 13 However, we did not see the pattern of diffuse global CNS expression of NaGlu that we expected based on our previous GFP studies using an i.v. vector injection with mannitol pretreatment. 13 This may be due to the low sensitivity of the anti-hNaGlu antibody, which only detects high level overexpression of the transgene (EF Neufeld, personal communication). While cells in the periventricular areas may have received multiple copies of the vector genome, it is likely that the isolated cells transduced by i.v. delivery would have been infected with a single vector. Alternatively, we note that the conventional single-strand rAAV-NaGlu vector used in this study would be expected to transduce cells less efficiently than the self-complementary AAV-GFP vector, resulting in a smaller number of cells transduced by i.v. delivery. We have recently optimized the delivery procedure for mannitol-facilitated CNS entry of i.v.-injected rAAV vector, and achieved an approximately 10-fold increase in the number of CNS cells expressing the transgene compared to the conditions used in the present study (unpublished data). Because the recombinant enzyme can be secreted and taken up by neighboring cells, a small number of transduction events in areas of the brain far removed from the ventricular system may have a significant beneficial effect. We anticipate that applying the optimized i.v. injection parameters for rAAV in the CNS may significantly augment gene delivery for the treatment of the neurological disorders of MPS IIIB, and may also be applied to therapeutic delivery for many other neurological diseases with global CNS pathology.
Although we demonstrated significant survival and behavioral benefits using our rAAV gene delivery strategy, the disparity between the measured levels of Increased lifespan and improved behavioral performances H Fu et al rNaGlu activity (supranormal in some cases), and the correction of lysosomal storage pathology in rAAVtreated MPS IIIB mouse brain, suggests that additional factors need to be considered for optimal MPS IIIB gene therapy. This disparity was also observed in studies on other LSD mouse models, even when treated by prenatal or neonatal CNS gene delivery, such as MPS VII, 35 Krabbe, 36 Niemann-Pick 23 and Sandhoff, 19, 37 as well as in ERT studies on LSDs regarding somatic tissues except liver. 7, [38] [39] [40] Previous studies showed that the secreted enzyme expressed from the hNaGlu cDNA was in the form of an 83 or 89 kDa precursor, while mature native hNaGlu is 77 kDa. 41, 42 Further, the rNaGlu was poorly manose-6-phosphorylated, 41, 42 and the majority of lysosomal enzymes are targeted to cells and lysosomes through mannose-6-phosphate (Man6-P) receptors. 1, 43 Though this isoform clearly can correct the enzymatic and lysosomal storage phenotype in human MPS IIIB skin fibroblasts, 17, 41, 42 efficient uptake and intracellular trafficking of secreted NaGlu by non-transduced cells is critical to effective gene therapy. Thus, the relatively low level of Man6-P addition, or other problems in posttranslational modification of the recombinant protein, may impede its therapeutic efficacy. Furthermore, it is known that LSDs often exhibit similar complex pathology cascades, 3 though they are single gene defects. We believe that the therapeutic efficacy of rAAV gene delivery for MPS IIIB will be greatly improved as research advances towards a better understanding of additional contributing factors involved in the disease.
We also demonstrated here a long-term complete correction of lysosomal storage in liver, and partial correction in multiple other somatic tissues, after i.v. infusion of the rAAV-NaGlu vector. This complete correction of lysosomal accumulation was achieved with only approximately 15-20% of liver cells expressing rNaglu, though liver is known to be the most efficient tissue for taking up rAAV vectors. This suggests that rNaGlu was secreted, and the secreted enzyme contributed to the correction of GAG storage in liver. Biodistribution studies in our laboratory (unpublished data) showed limited infectivity of rAAV2 to kidney, spleen and intestine compared to liver, after an i.v. vector injection, and this may explain the differential correction in these various tissues. However, it is also worth noting that this pattern of somatic correction is similar to that reported previously in ERT clinical studies on MPS I 38 and MPS II 7 patients and LSD animal models, 44-46 using i.v. infusion of the recombinant enzymes. It is therefore plausible that the differential correction may also be related to variable levels of uptake and catalytic function of the secreted recombinant enzymes in different tissues, which may be common among lysosomal enzymes. Unlike other LSDs, somatic therapy may not play a critical role in treating MPS IIIB patients because the early morbidity and mortality are largely attributable to the CNS manifestations of the disease. However, somatic pathology does exist in all MPS IIIB patients and animals, therefore, correction of the somatic lysosomal storage may provide some beneficial effects in general, and may become more important if the lifespan of the patients is extended due to effective treatment of neurological symptoms. It is likely that the somatic correction in MPS IIIB mice in this study resulted from the i.v.-delivered rAAV vector, since we have observed very limited somatic cell transduction, and only in mouse liver (in o0.1% of the cells), after an i.c. injection of rAAV2 vector (unpublished data).
In summary, we achieved significant therapeutic efficacy from rAAV2-mediated gene therapy for MPS IIIB in mice, using the combined i.v. and i.c. vector delivery. The parameters chosen for rAAV vector delivery in this study, including the mannitol pretreatment, the routes of vector delivery, and the volumes of injection, were based on suitability for human applications. These procedures are safe, non-surgical and minimally invasive, and may provide a basis for treating MPS IIIB in humans in the future.
Materials and methods

AAV viral vector
A rAAV2 viral vector plasmid was constructed as reported previously, 17 containing hNaGlu cDNA 47 controlled by a human CMV immediate early promoter. The AAV2 viral vector (AAV2-CMV-hNaGlu) was produced in 293 cells using three plasmid cotransfection, and purified on heparin affinity columns following previously published methods 48 by the Vector Core Facility, Gene Therapy Center, University of North Carolina at Chapel Hill, and the Vector Core Facility of Columbus Children's Research Institute. The viral vector contained only the minimal elements required for the expression of hNaGlu: AAV2 terminal repeats, CMV promoter, SV40 splice donor/acceptor signal, hNaGlu cDNA and SV40 polyadenylation (poly A) signal.
Animals
The MPS IIIB knock-out mouse model 2 
Delivery of rAAV viral vectors
To resemble potential therapeutic settings in humans, only juvenile mice, 4-8 weeks of age, were used in this study, since the BBB of mouse is not completely closed until 3 weeks after birth.
Each animal received both i.v. and i.c. injections of rAAV vector after pretreatment with an i.v. infusion of mannitol (1-2 mg/g bw) (25%, for i.v. use only, Abbott Laboratories, (Abbott Park, IL, USA) NDC0074-4031-01) to facilitate the CNS entry of i.v.-injected vector, and to enhance the spread of i.c.-injected vector, as demonstrated in previous studies. 13 The animals were anesthetized using 2.5% Avertin (0.38-0.43 mg/g bw) by intraperitoneal injection. An i.v. infusion of mannitol was administered through the tail vein to temporarily disrupt the BBB and facilitate the rAAV CNS entry. The AAV2-CMV-hNaGlu viral vector (4 Â 10 11 viral particles
Increased lifespan and improved behavioral performances H Fu et al in PBS (5-10 ml/g bw)) was then i.v.injected (over 1-2 min), 10 min after the mannitol pretreatment. I.c. injection was performed following a technique published previously. 13 The AAV2-CMV-hNaGlu viral vector (5 Â 10 10 viral particles in 15-20 ml PBS) was rapidly delivered into the posterior cistern of each MPS IIIB mouse, 15-20 min after mannitol pretreatment. Similarly, PBS (15-20 ml) was injected into the posterior cistern of control mice (4-8 weeks of age), including MPS IIIB mice and their wild-type littermates, 15-20 min after mannitol pretreatment. The control mice, including MPS IIIB mice and their wild-type littermates, were given an i.v. and an i.c. injection of PBS, instead of the vector, 10 and 20 min after mannitol pretreatment, respectively.
Assessment of longevity: lifespan and end point neuropathology
After the rAAV and sham injection(s), mice were continuously observed for the development of end point symptoms, or until death from natural causes occurred. In this study, the lifespan of the non-treated (sham injected) MPS IIIB mice varied from 8 to 12 months of age. All MPS IIIB mice were euthanized when the symptoms of late-stage clinical manifestation, such as urine retention, rectal prolapse, protruding penis and spinal curvature, became irreversible. Wild-type control mice were observed until they were 24 months or older. Behavioral tests (see below) were conducted to study the therapeutic benefits of the treatments on the neurological disorder in MPS IIIB mice. At the end of the experiments, multiple somatic tissues and the entire brains of the mice were collected on dry ice and stored at À701C, before being processed for NaGlu activity, GAG content, histopathology and TEM analyses.
NaGlu activity assay
The NaGlu enzyme activity assay was carried out following a previously published procedure. 49 The assay measures 4-methylumbelliferone, a fluorescent product formed by hydrolysis of the substrate 4-methylumbellireyl-N-acetyl-a-D-glucosaminide. The NaGlu activity is expressed as unit (U)/mg protein. One unit is equal to 1 nmol 4 MU released/h at 371C.
GAG content assay
Extraction of GAG from tissues was conducted following previously published procedures 50 with modification. The tissue samples were homogenized using a motordriven pestle before being digested in a solution (10 ml/mg tissue) containing: 50 mM phosphate buffer (pH 6.5), 2 mM ethylenediaminetetraacetic acid, 2 mM cysteine and 0.5 mg/ml papain. After incubation at 561C overnight, the reaction was stopped by incubation at 961C for 1 min, and then chilled on ice. Protein was precipitated using trichloroacetic acid (6%) on ice for 2 h, and removed by centrifugation at 10 000 r.p.m. at 41C for 20 min. The GAG was precipitated by adding 4 volumes of absolute ethanol to the supernatant and placed at À201C overnight before being centrifuged at 10 000 r.p.m. for 30 min. GAG precipitates were air-dried and then dissolved in H 2 O. Dimethylmethylene blue (DMB) 51 assay was used to measure GAG content. The GAG samples (from 0.5 to 1.0 mg tissue) were mixed with H 2 O to 40 ml before adding 35 nM DMB (Polysciences Cat# 03610-1) in 0.2 mM sodium formate buffer (pH 3.5). The product was measured (OD 535 ) using a spectrophotometer. The GAG content was expressed as mg/mg tissue. Heparan sulfate (Sigma, Cat# H9637) was used as standard control.
Histopathology
Histopathology was conducted following standard methods. Tissue samples were embedded in OCT compound (Sakura Finetek USA Inc., Torrance, CA, USA), and fast frozen on dry ice for cryostat sectioning. Thin sections (8 mm) were fixed with 4% paraformaldehyde in phosphate buffer (0.1 M, pH 7.2) at 41C for 15 min and stained with 1% toluidine blue at 371C for 30 min. The sections were mounted, after being dehydrated in absolute isopropanol for 1 min and cleared in xylene and visualized under light microscope.
Processing brain samples for analysis
Entire brains were embedded in OCT compound and fast frozen on dry ice. Using a cryostat, serial thin transverse sections (8 mm) were obtained for histopathology, and alternated with thick sections (50 mm) for NaGlu activity and GAG assay, as described above.
IHC for hNaGlu
The rAAV-expressed hNaGlu was detected using polyclonal antibody (a kind gift from Dr EF Neufeld, UCLA) that does not crossreact with mouse NaGlu enzyme. IHC was carried out on thin cryostat sections (8 mm) from liver and brain samples of experimental subjects, using a biotinylated secondary antibody (Sigma-Aldrich, St Louis, MO, USA, Cat#. B-8895) and streptavidin-conjugated alkaline phosphatase (Chemicon International Inc., Temecula, CA, USA) Cat#. SA204). The IHC staining was conducted following the instructions provided by the manufacturers.
TEM
The liver samples for TEM were fixed in 2.5% of glutaraldehyde in PBS (pH 7.2). Tissue processing was conducted by the microscopy facility at UNC-CH.
Behavioral studies
Behavioral tests were conducted in the Mouse Behavioral Phenotyping Laboratory, Neurodevelopmental Disorders Research Center, University of North Carolina at Chapel Hill. Groups included 11 wild-type mice, 25 MPS IIIB mice that received sham i.v. and i.c. injections and 19 MPS IIIB mice treated with rAAV vector by the combination of i.v. and i.c. injections. These subjects belonged to the same age group (with 3-4 weeks difference), which were available at the time of behavioral testing.
Mice were divided into four cohort groups, based on age, and tested with the same set of sequential behavioral tasks. Testing began when mice were approximately 4.5-5 months in age.
Elevated plus maze test for anxiety-like responses. Mice were given one 5-min trial on the plus maze, 52 which had two walled arms (the closed arms, 40 cm in height, 21 cm in length) and two open arms (21 cm length). The maze was elevated 50 cm from the floor, and constructed from 52 Counts were taken of the number of photobeams broken during the trial, with separate measures for locomotion (breaking of contiguous photobeams), vertical activity (breaking of upper-level photobeams) and discrete rearing movements.
Rotarod. Subjects were tested on an accelerating rotarod (Ugo Basile, Stoelting Co., Wood Dale, IL, USA) to assess motor coordination. 52 For the first test session, animals were given three trials, with 45 s between each trial. Two additional trials were given 48 h later. R.p.m. was set at an initial value of three, with a progressive increase to a maximum of 30 r.p.m. across 5 min (the maximum trial length). Measures were taken for latency to fall from the top of the rotating barrel.
Acoustic startle. The acoustic startle test was used to assess auditory function and sensory-motor gating. 52 The test measured the reflexive whole-body flinch, or startle response, that follows exposure to a sudden noise. Assessments were made of startle magnitude and of prepulse inhibition, which occurs when a weak prestimulus leads to a reduced startle in response to a subsequent louder noise. For this study, animals were tested with a San Diego Instruments SR-Lab System. Briefly, mice were placed in a small Plexiglas cylinder within a larger, sound-attenuating chamber (San Diego Instruments, San Diego, CA, USA). The cylinder was seated upon a piezoelectric transducer, which allowed vibrations to be quantified and displayed on a computer. The chamber included a houselight, fan, and a loudspeaker for the acoustic stimuli. Background sound levels (70 dB) and calibration of the acoustic stimuli were confirmed with a digital sound level meter (San Diego Instruments).
Each mouse was given one session, consisting of 42 trials, which began with a 5-min habituation period. There were seven different types of trials: the nostimulus trials, trials with the acoustic startle stimulus (40 ms; 120 dB) alone, and trials in which a prepulse stimulus (20 ms; either 74, 78, 82, 86, or 90 dB) occurred 100 ms before the onset of the startle stimulus. Measures were taken of the startle amplitude for each trial across a 65-ms sampling window, and an overall analysis was performed for each subject's data for levels of prepulse inhibition at each prepulse sound level (calculated as 100À(response amplitude for prepulse stimulus and startle stimulus together/response amplitude for startle stimulus alone) Â 100).
Visual cue task in the Morris water maze. The water maze consisted of a large circular pool (diameter ¼ 122 cm) filled with water (45 cm deep, 24-261C), located in a room with numerous visual cues. 53 Mice were tested for their ability to find a visible escape platform (diameter ¼ 15 cm). The location of the platform was signaled by a tall cylinder, marked with a distinctive pattern, placed on the center of the platform surface. Each animal was given four trials per day, across 3 days. For each trial, the mouse was placed in the pool at one of four possible locations (randomly ordered), and then given 60 s to swim to the escape platform. If the mouse found the platform, the trial ended, and the animal was allowed to remain 10 s on the platform before the next trial began. If the platform was not found, the mouse was placed on the platform for 10 s, and then given the next trial. Measures were taken of latency to find the platform and swimming velocity via an automated tracking system (Noldus Ethovision, Leesburg, VA, USA).
Data were analyzed using repeated measures analysis of variance (ANOVA), with factors experimental group and sex. Separate one-way ANOVAs were conducted to examine group differences at each time point. Fisher's protected least-significant difference tests were used for comparing group means only when a significant F-value was determined. For all comparisons, significance was set at Po0.05.
